Editorial: aminosalicylates in Crohn's disease-prevalence, risks, costs and time to reassess? Authors' reply

V Jairath^{1

2

3}, C Ma^{3

4}, B Feagan^{1

2

3}

Affiliations

¹ Division of Gastroenterology, Department Medicine, Schulich School of Medicine, Western University, London, ON, Canada.
² Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
³ Robarts Clinical Trial, London, ON, Canada.
⁴ University of Calgary, Calgary, Canada.

Editorial

V Jairath et al. Aliment Pharmacol Ther. 2018 Aug.

. 2018 Aug;48(4):489.

doi: 10.1111/apt.14908.

V Jairath^{1

2

3}, C Ma^{3

4}, B Feagan^{1

2

3}

¹ Division of Gastroenterology, Department Medicine, Schulich School of Medicine, Western University, London, ON, Canada.
² Department of Epidemiology and Biostatistics, Western University, London, ON, Canada.
³ Robarts Clinical Trial, London, ON, Canada.
⁴ University of Calgary, Calgary, Canada.

No abstract available

Comment on

Systematic review with meta-analysis: prevalence, risk factors and costs of aminosalicylate use in Crohn's disease.
Ma C, Dutton SJ, Cipriano LE, Singh S, Parker CE, Nguyen TM, Guizzetti L, Gregor JC, Chande N, Hindryckx P, Feagan BG, Jairath V. Ma C, et al. Aliment Pharmacol Ther. 2018 Jul;48(2):114-126. doi: 10.1111/apt.14821. Epub 2018 May 30. Aliment Pharmacol Ther. 2018. PMID: 29851091
Editorial: aminosalicylates in Crohn's disease-prevalence, risks, costs and time to re-assess?
Mansfield J, MacDougall L. Mansfield J, et al. Aliment Pharmacol Ther. 2018 Aug;48(4):487-488. doi: 10.1111/apt.14859. Aliment Pharmacol Ther. 2018. PMID: 30588694 No abstract available.